<DOC>
	<DOCNO>NCT01115803</DOCNO>
	<brief_summary>Study JGCB multicenter , nonrandomized , open-label , dose-escalation Phase 1b study LY2584702 combination either erlotinib everolimus .</brief_summary>
	<brief_title>A Study LY2584702 With Erlotinib Everolimus Patients With Solid Tumors</brief_title>
	<detailed_description>Study JGCB consist follow part : Part 1 - Dose Escalation maximum tolerate dose arm . Arm A - LY2584702 + Erlotinib patient advance metastatic cancer . Arm B - LY2584702 + Everolimus patient advance metastatic cancer . Part 2 - Dose Confirmation maximum tolerate dose arm Part 1 . Arm A - LY2584702 + Erlotinib patient advance metastatic non-small cell lung cancer . Arm B - LY2584702 + Everolimus patient advance renal cell carcinoma treatment failure sunitinib sorafenib , advanced neuroendocrine tumor .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Dose Escalation portion ( Part 1 ) : histological cytological evidence diagnosis cancer advance and/or metastatic disease ( include NonHodgkin 's Lymphoma ) proven effective therapy exists . Dose Confirmation portion ( Part 2 ) : histological cytological evidence : 1 . Arm A : advanced metastatic nonsmall cell lung cancer failure least one prior chemotherapy regimen . 2 . Arm B : advanced renal cell carcinoma failure treatment sunitinib sorafenib , advanced neuroendocrine tumor . Have presence measurable nonmeasurable disease define Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) Revised Response Criteria Malignant Lymphoma . 1 . Dose Escalation portion ( Part 1 ) : patient may measurable nonmeasurable disease . 2 . Dose Confirmation portion ( Part 2 ) : patient must measurable disease . Have adequate organ function include : 1 . Hematologic : absolute neutrophil count ( ANC ) great equal 1.5 x 109/L , platelet great equal 100 x 109/L , hemoglobin great equal 8 g/dL . 2 . Hepatic : bilirubin le equal 1.5 time upper limit normal ( ULN ) ; alanine transaminase ( ALT ) AST le equal 2.5 time ULN . If liver tumor involvement , AST ALT equal less equal 5 time ULN acceptable . Patients bone metastasis may enter alkaline phosphatase value less equal 5 time ULN , long hepatic parameter meet inclusion criterion . 3 . Renal : Serum creatinine less equal 1.5 time ULN calculate creatinine clearance &gt; 45 ml/mn . Have performance status less equal 1 Eastern Cooperative Oncology Group ( ECOG ) scale . Have discontinue previous therapy cancer , include chemotherapy , radiotherapy , cancerrelated hormonal therapy , investigational therapy least 2 week ( 3 week myelosuppressive agent ) prior study enrollment , recover acute effect therapy . At discretion investigator , patient prostate cancer progress LHRH agonist therapy , patient adrenal carcinoma use mitotan , may treatment continue receive study drug . Have receive treatment drug receive regulatory approval indication within 14 21 day initial dose study drug nonmyelosuppressive myelosuppressive agent , respectively . Have serious preexist medical condition , opinion investigator , would preclude participation study . Have symptomatic CNS malignancy metastasis . Patients treat CNS metastasis eligible provided disease radiographically stable asymptomatic , currently receive corticosteroid and/or anticonvulsant . Screening asymptomatic patient without history CNS metastasis require . Concomitant treatment strong CYP3A4 inhibitor CYP3A4 inducer . Have acute chronic leukemia . Have receive autologous allogeneic stemcell transplant within 75 day initial dose study drug . In addition , recipient allogenic stemcell transplant must discontinue immunosuppressive therapy least 24 hour study drug administration Grade 1 acute graftversushost disease . For Dose Confirmation portion ( Part 2 ) : previously receive erlotinib Arm A everolimus Arm B .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>Metastatic Cancer</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Neuroendocrine Tumors</keyword>
</DOC>